M&T Bank Corp Kodiak Sciences Inc. Transaction History

M&T Bank Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$7.09 - $89.45 $27,502 - $346,976	-3,879 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$77.2 - $126.54 $65,002 - $106,546	842 Added 27.72%	3,879 $361,000
Q1 2021 May 06, 2021	SELL	$110.45 - $164.47 $3,092 - $4,605	-28 Reduced 0.91%	3,037 $344,000
Q4 2020 Feb 12, 2021	SELL	$60.78 - $154.03 $90,440 - $229,196	-1,488 Reduced 32.68%	3,065 $450,000
Q3 2020 Nov 06, 2020	BUY	$45.05 - $59.27 $205,112 - $269,856	4,553 New	4,553 $270,000
Q1 2020 May 14, 2020	SELL	$38.18 - $73.95 $182,080 - $352,667	-4,769 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$13.9 - $76.65 $133,884 - $738,292	-9,632 Reduced 66.88%	4,769 $343,000
Q3 2019 Nov 12, 2019	SELL	$10.24 - $17.57 $16,384 - $28,112	-1,600 Reduced 10.0%	14,401 $207,000
Q2 2019 Aug 12, 2019	SELL	$6.2 - $12.0 $19,728 - $38,184	-3,182 Reduced 16.59%	16,001 $187,000
Q1 2019 May 15, 2019	BUY	$6.43 - $9.44 $123,346 - $181,087	19,183 New	19,183 $125,000

109

40.9M

28.4K

21.2K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $183M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.